 | • レポートコード：GIR-23F3859 • 出版社/出版日：GlobalInfoResearch / 2023年2月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、79ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Meningococcal Group B Vaccine Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界のB群髄膜炎菌ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 B群髄膜炎菌ワクチン市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・ベクセロ、トルメンバ、その他 アプリケーション別セグメントは次のように区分されます。 ・公共事業、民営事業 世界のB群髄膜炎菌ワクチン市場の主要なマーケットプレーヤーは以下のとおりです。 ・GSK、Pfizer 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - B群髄膜炎菌ワクチンの概要 - タイプ別分析（2017年vs2021年vs2028年）：ベクセロ、トルメンバ、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：公共事業、民営事業 - 世界のB群髄膜炎菌ワクチン市場規模・予測 - 世界のB群髄膜炎菌ワクチン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - GSK、Pfizer ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：ベクセロ、トルメンバ、その他 ・アプリケーション別分析2017年-2028年：公共事業、民営事業 ・B群髄膜炎菌ワクチンの北米市場分析 - B群髄膜炎菌ワクチンの北米市場：タイプ別市場規模2017年-2028年 - B群髄膜炎菌ワクチンの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・B群髄膜炎菌ワクチンのヨーロッパ市場分析 - ：B群髄膜炎菌ワクチンのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：B群髄膜炎菌ワクチンのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・B群髄膜炎菌ワクチンのアジア太平洋市場分析 - B群髄膜炎菌ワクチンのアジア太平洋市場：タイプ別市場規模2017年-2028年 - B群髄膜炎菌ワクチンのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・B群髄膜炎菌ワクチンの南米市場分析 - B群髄膜炎菌ワクチンの南米市場：タイプ別市場規模2017年-2028年 - B群髄膜炎菌ワクチンの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・B群髄膜炎菌ワクチンの中東・アフリカ市場分析 - B群髄膜炎菌ワクチンの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - B群髄膜炎菌ワクチンの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Meningococcal Group B Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Meningococcal Group B Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Public accounting for % of the Meningococcal Group B Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Bexsero segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Meningococcal Group B Vaccine include GSK, Pfizer, , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Meningococcal Group B Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Bexsero
Trumenba
Other
Market segment by Application can be divided into
Public
Private
The key market players for global Meningococcal Group B Vaccine market are listed below:
GSK
Pfizer
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Meningococcal Group B Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Meningococcal Group B Vaccine, with price, sales, revenue and global market share of Meningococcal Group B Vaccine from 2019 to 2022.
Chapter 3, the Meningococcal Group B Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Group B Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Meningococcal Group B Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Meningococcal Group B Vaccine.
Chapter 13, 14, and 15, to describe Meningococcal Group B Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Meningococcal Group B Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Meningococcal Group B Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Bexsero
1.2.3 Trumenba
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Meningococcal Group B Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Public
1.3.3 Private
1.4 Global Meningococcal Group B Vaccine Market Size & Forecast
1.4.1 Global Meningococcal Group B Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Meningococcal Group B Vaccine Sales in Volume (2017-2028)
1.4.3 Global Meningococcal Group B Vaccine Price (2017-2028)
1.5 Global Meningococcal Group B Vaccine Production Capacity Analysis
1.5.1 Global Meningococcal Group B Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Meningococcal Group B Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Meningococcal Group B Vaccine Market Drivers
1.6.2 Meningococcal Group B Vaccine Market Restraints
1.6.3 Meningococcal Group B Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Meningococcal Group B Vaccine Product and Services
2.1.4 GSK Meningococcal Group B Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Meningococcal Group B Vaccine Product and Services
2.2.4 Pfizer Meningococcal Group B Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Meningococcal Group B Vaccine Breakdown Data by Manufacturer
3.1 Global Meningococcal Group B Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Meningococcal Group B Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Meningococcal Group B Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Meningococcal Group B Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Meningococcal Group B Vaccine Manufacturer Market Share in 2021
3.5 Global Meningococcal Group B Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Meningococcal Group B Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Meningococcal Group B Vaccine Market Size by Region
4.1.1 Global Meningococcal Group B Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Meningococcal Group B Vaccine Revenue by Region (2017-2028)
4.2 North America Meningococcal Group B Vaccine Revenue (2017-2028)
4.3 Europe Meningococcal Group B Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Meningococcal Group B Vaccine Revenue (2017-2028)
4.5 South America Meningococcal Group B Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Meningococcal Group B Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Meningococcal Group B Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Meningococcal Group B Vaccine Revenue by Type (2017-2028)
5.3 Global Meningococcal Group B Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Meningococcal Group B Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Meningococcal Group B Vaccine Revenue by Application (2017-2028)
6.3 Global Meningococcal Group B Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Meningococcal Group B Vaccine Sales by Type (2017-2028)
7.2 North America Meningococcal Group B Vaccine Sales by Application (2017-2028)
7.3 North America Meningococcal Group B Vaccine Market Size by Country
7.3.1 North America Meningococcal Group B Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Meningococcal Group B Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Meningococcal Group B Vaccine Sales by Type (2017-2028)
8.2 Europe Meningococcal Group B Vaccine Sales by Application (2017-2028)
8.3 Europe Meningococcal Group B Vaccine Market Size by Country
8.3.1 Europe Meningococcal Group B Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Meningococcal Group B Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Meningococcal Group B Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Meningococcal Group B Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Meningococcal Group B Vaccine Market Size by Region
9.3.1 Asia-Pacific Meningococcal Group B Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Meningococcal Group B Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Meningococcal Group B Vaccine Sales by Type (2017-2028)
10.2 South America Meningococcal Group B Vaccine Sales by Application (2017-2028)
10.3 South America Meningococcal Group B Vaccine Market Size by Country
10.3.1 South America Meningococcal Group B Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Meningococcal Group B Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Meningococcal Group B Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Meningococcal Group B Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Meningococcal Group B Vaccine Market Size by Country
11.3.1 Middle East & Africa Meningococcal Group B Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Meningococcal Group B Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Meningococcal Group B Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Meningococcal Group B Vaccine
12.3 Meningococcal Group B Vaccine Production Process
12.4 Meningococcal Group B Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Meningococcal Group B Vaccine Typical Distributors
13.3 Meningococcal Group B Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Meningococcal Group B Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Meningococcal Group B Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. GSK Basic Information, Manufacturing Base and Competitors
Table 4. GSK Major Business
Table 5. GSK Meningococcal Group B Vaccine Product and Services
Table 6. GSK Meningococcal Group B Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Major Business
Table 9. Pfizer Meningococcal Group B Vaccine Product and Services
Table 10. Pfizer Meningococcal Group B Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Global Meningococcal Group B Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 12. Global Meningococcal Group B Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 13. Market Position of Manufacturers in Meningococcal Group B Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 14. Global Meningococcal Group B Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 15. Head Office and Meningococcal Group B Vaccine Production Site of Key Manufacturer
Table 16. Meningococcal Group B Vaccine New Entrant and Capacity Expansion Plans
Table 17. Meningococcal Group B Vaccine Mergers & Acquisitions in the Past Five Years
Table 18. Global Meningococcal Group B Vaccine Sales by Region (2017-2022) & (K Units)
Table 19. Global Meningococcal Group B Vaccine Sales by Region (2023-2028) & (K Units)
Table 20. Global Meningococcal Group B Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 21. Global Meningococcal Group B Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 22. Global Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 23. Global Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 24. Global Meningococcal Group B Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 25. Global Meningococcal Group B Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 26. Global Meningococcal Group B Vaccine Price by Type (2017-2022) & (USD/Unit)
Table 27. Global Meningococcal Group B Vaccine Price by Type (2023-2028) & (USD/Unit)
Table 28. Global Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 29. Global Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 30. Global Meningococcal Group B Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 31. Global Meningococcal Group B Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 32. Global Meningococcal Group B Vaccine Price by Application (2017-2022) & (USD/Unit)
Table 33. Global Meningococcal Group B Vaccine Price by Application (2023-2028) & (USD/Unit)
Table 34. North America Meningococcal Group B Vaccine Sales by Country (2017-2022) & (K Units)
Table 35. North America Meningococcal Group B Vaccine Sales by Country (2023-2028) & (K Units)
Table 36. North America Meningococcal Group B Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 37. North America Meningococcal Group B Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 38. North America Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 39. North America Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 40. North America Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 41. North America Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 42. Europe Meningococcal Group B Vaccine Sales by Country (2017-2022) & (K Units)
Table 43. Europe Meningococcal Group B Vaccine Sales by Country (2023-2028) & (K Units)
Table 44. Europe Meningococcal Group B Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 45. Europe Meningococcal Group B Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 46. Europe Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 47. Europe Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 48. Europe Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 49. Europe Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 50. Asia-Pacific Meningococcal Group B Vaccine Sales by Region (2017-2022) & (K Units)
Table 51. Asia-Pacific Meningococcal Group B Vaccine Sales by Region (2023-2028) & (K Units)
Table 52. Asia-Pacific Meningococcal Group B Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 53. Asia-Pacific Meningococcal Group B Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 54. Asia-Pacific Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 55. Asia-Pacific Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 56. Asia-Pacific Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 57. Asia-Pacific Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 58. South America Meningococcal Group B Vaccine Sales by Country (2017-2022) & (K Units)
Table 59. South America Meningococcal Group B Vaccine Sales by Country (2023-2028) & (K Units)
Table 60. South America Meningococcal Group B Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 61. South America Meningococcal Group B Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 62. South America Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 63. South America Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 64. South America Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 65. South America Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 66. Middle East & Africa Meningococcal Group B Vaccine Sales by Region (2017-2022) & (K Units)
Table 67. Middle East & Africa Meningococcal Group B Vaccine Sales by Region (2023-2028) & (K Units)
Table 68. Middle East & Africa Meningococcal Group B Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 69. Middle East & Africa Meningococcal Group B Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 70. Middle East & Africa Meningococcal Group B Vaccine Sales by Type (2017-2022) & (K Units)
Table 71. Middle East & Africa Meningococcal Group B Vaccine Sales by Type (2023-2028) & (K Units)
Table 72. Middle East & Africa Meningococcal Group B Vaccine Sales by Application (2017-2022) & (K Units)
Table 73. Middle East & Africa Meningococcal Group B Vaccine Sales by Application (2023-2028) & (K Units)
Table 74. Meningococcal Group B Vaccine Raw Material
Table 75. Key Manufacturers of Meningococcal Group B Vaccine Raw Materials
Table 76. Direct Channel Pros & Cons
Table 77. Indirect Channel Pros & Cons
Table 78. Meningococcal Group B Vaccine Typical Distributors
Table 79. Meningococcal Group B Vaccine Typical Customers
List of Figures
Figure 1. Meningococcal Group B Vaccine Picture
Figure 2. Global Meningococcal Group B Vaccine Revenue Market Share by Type in 2021
Figure 3. Bexsero
Figure 4. Trumenba
Figure 5. Other
Figure 6. Global Meningococcal Group B Vaccine Revenue Market Share by Application in 2021
Figure 7. Public
Figure 8. Private
Figure 9. Global Meningococcal Group B Vaccine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Meningococcal Group B Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Meningococcal Group B Vaccine Sales (2017-2028) & (K Units)
Figure 12. Global Meningococcal Group B Vaccine Price (2017-2028) & (USD/Unit)
Figure 13. Global Meningococcal Group B Vaccine Production Capacity (2017-2028) & (K Units)
Figure 14. Global Meningococcal Group B Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Meningococcal Group B Vaccine Market Drivers
Figure 16. Meningococcal Group B Vaccine Market Restraints
Figure 17. Meningococcal Group B Vaccine Market Trends
Figure 18. Global Meningococcal Group B Vaccine Sales Market Share by Manufacturer in 2021
Figure 19. Global Meningococcal Group B Vaccine Revenue Market Share by Manufacturer in 2021
Figure 20. Meningococcal Group B Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Meningococcal Group B Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Meningococcal Group B Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Meningococcal Group B Vaccine Sales Market Share by Region (2017-2028)
Figure 24. Global Meningococcal Group B Vaccine Revenue Market Share by Region (2017-2028)
Figure 25. North America Meningococcal Group B Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Europe Meningococcal Group B Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Meningococcal Group B Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. South America Meningococcal Group B Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Meningococcal Group B Vaccine Revenue (2017-2028) & (USD Million)
Figure 30. Global Meningococcal Group B Vaccine Sales Market Share by Type (2017-2028)
Figure 31. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2017-2028)
Figure 32. Global Meningococcal Group B Vaccine Price by Type (2017-2028) & (USD/Unit)
Figure 33. Global Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 34. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2017-2028)
Figure 35. Global Meningococcal Group B Vaccine Price by Application (2017-2028) & (USD/Unit)
Figure 36. North America Meningococcal Group B Vaccine Sales Market Share by Type (2017-2028)
Figure 37. North America Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 38. North America Meningococcal Group B Vaccine Sales Market Share by Country (2017-2028)
Figure 39. North America Meningococcal Group B Vaccine Revenue Market Share by Country (2017-2028)
Figure 40. United States Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Meningococcal Group B Vaccine Sales Market Share by Type (2017-2028)
Figure 44. Europe Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 45. Europe Meningococcal Group B Vaccine Sales Market Share by Country (2017-2028)
Figure 46. Europe Meningococcal Group B Vaccine Revenue Market Share by Country (2017-2028)
Figure 47. Germany Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Meningococcal Group B Vaccine Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Meningococcal Group B Vaccine Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Meningococcal Group B Vaccine Revenue Market Share by Region (2017-2028)
Figure 56. China Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Meningococcal Group B Vaccine Sales Market Share by Type (2017-2028)
Figure 63. South America Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 64. South America Meningococcal Group B Vaccine Sales Market Share by Country (2017-2028)
Figure 65. South America Meningococcal Group B Vaccine Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Meningococcal Group B Vaccine Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Meningococcal Group B Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Meningococcal Group B Vaccine in 2021
Figure 77. Manufacturing Process Analysis of Meningococcal Group B Vaccine
Figure 78. Meningococcal Group B Vaccine Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
| 【B群髄膜炎菌ワクチンについて】 B群髄膜炎菌ワクチン（Meningococcal Group B Vaccine）は、細菌性髄膜炎の一種である超髄膜炎の予防を目的としたワクチンです。髄膜炎菌は、特に小児や若年者において重篤な感染症を引き起こし、場合によっては生命にかかわることがあります。B群髄膜炎菌は、特に西洋諸国では感染率が高く、そのためこのワクチンは重要な予防手段とされています。 B群髄膜炎菌ワクチンの定義として、主にB群に属するNeisseria meningitidis（髄膜炎菌）の中で、特にその持つ表面抗原に基づいた成分を利用して作られたワクチンを指します。これにより、体内で抗体が生成され、感染予防に寄与します。髄膜炎菌は、主に接触を介して人から人へと感染し、喉や鼻の粘膜で増殖し、最終的に血流に乗って脳や脊髄の膜に達し、髄膜炎を引き起こします。特にB群においては、重症の感染症を引き起こすため、ワクチン接種が推奨されます。 B群髄膜炎菌ワクチンにはいくつかの特徴があります。まず、B群髄膜炎菌は多様な抗原構造を持っており、そのためワクチン製造は非常に難解です。これまでの伝統的なワクチンは、細菌の細胞壁成分を基にした不活化ワクチンやトキソイドワクチンが主流でしたが、B群特有の多様性のため、従来の方法では効果的なワクチンの開発が難しいとされてきました。現在は、遺伝子工学の進展により、抗原の選択的表現やサブユニットワクチンの開発が可能となり、より効果的なワクチンの製造が進められています。 B群髄膜炎菌ワクチンには、主に2つのタイプが存在します。一つは、純粋なポリサッカライドワクチンであり、もう一つはリコンビナントワクチンです。ポリサッカライドワクチンは、B群髄膜菌の細胞壁に含まれる多糖体を利用して作られ、これにより免疫応答を誘導します。しかし、このタイプのワクチンは、誘導される免疫の持続期間が短く、特に若年者や幼児には十分な免疫を与えることができない場合があります。一方、リコンビナントワクチンは、遺伝子組換え技術を用いて特定のタンパク質を標的としており、より強い免疫応答を期待できる特徴を持っています。 B群髄膜炎菌ワクチンの用途は、主に感染予防ですが、特にリスクの高い集団において重要です。たとえば、大学や寮に住む学生、軍隊の兵士、またはHIV感染者など、免疫力が低下している場合には、ワクチン接種が特に推奨されます。また、ワクチン接種の普及により、髄膜炎の発生率が劇的に低下した国も存在します。特に欧米諸国では、集団接種プログラムを通じて髄膜炎菌による感染症を防ぐ努力がなされています。 関連技術としては、ワクチンの効果を向上させるための研究が進められています。たとえば、アジュバントと呼ばれる添加物を使用することで、免疫応答を強化する試みや、新たな投与方法の開発、ワクチンの冷凍保存技術などが進展しています。また、遺伝子治療技術を用いた新しいワクチンの開発も進められています。 最後に、B群髄膜炎菌ワクチンは、公共衛生の観点からも非常に重要な役割を果たしています。髄膜炎の発生を防ぐことで、患者の苦痛を減少させ、医療システムへの負担を軽減することができます。ワクチン接種による集団免疫の形成は、特に免疫力が低い人々を守るためにも不可欠です。今後もさらに研究と改良を進め、より効果的で安全なワクチンの開発が期待されています。 |